Tvardi Therapeutics Inc (TVRD) Institutional Ownership & 13F Filings (Q2 2026)

TVRD ranks #5737 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

59 institutions disclose a position in TVRD, but none treat it as a major bet — even American Financial Group Inc, its most concentrated holder, allocates just 0.1% of its own portfolio to it.

UBS Group AG has added to its TVRD position for two straight quarters, increasing it by $58.3K to reach $211.2K today.

Slate Path Capital LP has trimmed its TVRD position for two straight quarters, cutting it by $1.7M while still holding $1.3M.

TVRD reported a net loss of $26.1M over the trailing twelve months.

• Not yet profitable — net loss of $26.1M over the trailing twelve months
• Revenue declined 55.3% year over year
• Net income declined year over year, from $22.9M to -$26.1M
• Operating cash flow was negative, using $23.5M in cash
• Current ratio of 2.86x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.53x equity — within a conventional range